Good news: Pharma narrowly beats for-profit health insurers in corporate reputation survey
This article was originally published in Scrip
Executive Summary
A new report shows that just 35% of patient groups believe pharma had a 'good' or 'excellent' reputation in 2013. The independent study, funded by PatientView, surveyed 800 patient groups on their impressions of eight healthcare industries including the pharma industry, plus the corporate reputation of 33 individual pharma companies.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.